Ten years later, Lilly's long-term Alzheimer's trial of solanezumab has definitively failed
A trial of Eli Lilly’s Alzheimer’s drug solanezumab that began in 2013 didn’t show any benefit in patients, who were followed for a decade to try and answer whether the amyloid-targeting drug might slow the disease.
Lilly’s study enrolled about 1,100 patients ages 65 to 85 who had yet to show signs of clinical impairment but who had brain imaging scans showing amyloid plaque accumulation, an early diagnostic signal of Alzheimer’s. Patients got the drug for four and a half years and were followed for the rest of the study — far longer than the year or two that’s more common for such trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
